BioMS Medical to participate in bioindustry session at BioPartnering North America

    Toronto Stock Exchange Symbol: MS

    EDMONTON, Feb. 6 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
Ms. Amanda Stadel, Investor Relations Manager, will present at a session
hosted by BioAlberta, Alberta's life science industry association, as part of
the 7th Annual BioPartnering North America Conference in Vancouver.
    This workshop will profile activities within Alberta's world-class health
and biotechnology institutes as well as showcase companies that are active in
the region.

    TITLE:    "Need + Innovation = Opportunity...Alberta, Canada"

    WHEN:     Monday February 9th at 4:30pm (Pacific Time)

    WHERE:    Westin Bayshore Resort, Vancouver

    About BioPartnering North America
    BioPartnering North America brings together decision-makers from leading
biotechnology, pharmaceutical and investment companies and features company
presentations, partnering meetings and expert panels and workshops. For more
information visit

    About BioAlberta
    BioAlberta is a private, not-for-profit industry association, representing
Alberta's growing bioindustry. For more information visit

    About BioMS Medical Corp.

    BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, dirucotide, is for the treatment of multiple sclerosis and is
being evaluated in two pivotal phase III clinical trials for Secondary
Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the
United States. In December 2007, BioMS entered into a licensing and
development agreement granting Eli Lilly and Company exclusive worldwide
rights to dirucotide in exchange for an $87 million upfront payment, milestone
payments and escalating royalties on sales. For further information please
visit our website at

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that dirucotide will continue to demonstrate a satisfactory
safety profile in ongoing and future clinical trials; and that BioMS Medical
Corp. will complete the respective clinical trials within the timelines
communicated in this release. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

For further information:

For further information: Tony Hesby, Ryan Giese, Amanda Stadel, BioMS
Medical Corp., (780) 413-7152, (780) 408-3040 Fax, E-mail:, Internet:; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail:

Organization Profile

Medwell Capital Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890